Skip to main content
Premium Trial:

Request an Annual Quote

Response Biomedical Receives Chinese Clearance for Ramp 200

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Biomedical announced on Thursday that China's State Food & Drug Administration has approved its Ramp 200 Reader for marketing in China.

In a statement, Response Biomedical CEO S. Wayne Kay called the approval "a pivotal step forward in increasing our market penetration in this region."

According to the Vancouver, British Columbia-based company, China spent $120 billion last year establishing universal healthcare coverage and is expected to build 400 new hospitals each year during the next decade. The market for in vitro diagnostic products in the country is estimated at $2 billion per year with a growth rate of between 15 percent and 20 percent for the next five years.

China is expected to become the third-largest consumer of IVD products in the world by 2015, it added.

"The market potential for our diagnostic products in China is rapidly expanding and we believe we have the necessary resources and partnerships in place to meet the growing market demand for Ramp 200 and our cardiac diagnostic tests," Kay said.

Response Biomedical's distributor in China, O&D Biotech China, assisted in the approval process, the company said.

The Ramp 200 platform is a diagnostic instrument for clinical and environmental applications. It can run 18 tests per hour on one module and up to 36 tests per hour using three modules, allowing tests to be run on multiple patient samples simultaneously or multiple assays for one patient, Response Biomedical said.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.